Bile duct obstruction is a potent stimulus for cholangiocyte proliferation, especially for large cholangiocytes. Our previous studies reported that conjugated bile acids (CBAs) activate the protein kinase B (AKT) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathways through sphingosine 1-phosphate receptor (S1PR) 2 in hepatocytes and cholangiocarcinoma cells. It also has been reported that taurocholate (TCA) promotes large cholangiocyte proliferation and protects cholangiocytes from bile duct ligation (BDL)-induced apoptosis. However, the role of S1PR2 in bile-acid-mediated cholangiocyte proliferation and cholestatic liver injury has not been elucidated. Here, we report that S1PR2 is the predominant S1PR expressed in cholangiocytes. Both TCA-and sphingosine-1-phosphate (S1P)-induced activation of ERK1/2 and AKT were inhibited by JTE-013, a specific antagonist of S1PR2, in cholangiocytes. In addition, TCA-and S1P-induced cell proliferation and migration were inhibited by JTE-013 and a specific short hairpin RNA of S1PR2, as well as chemical inhibitors of ERK1/2 and AKT in mouse cholangiocytes. In BDL mice, expression of S1PR2 was up-regulated in whole liver and cholangiocytes. S1PR2 deficiency significantly reduced BDL-induced cholangiocyte proliferation and cholestatic injury, as indicated by significant reductions in inflammation and liver fibrosis in S1PR2 knockout mice. Treatment of BDL mice with JTE-013 significantly reduced total bile acid levels in serum and cholestatic liver injury. Conclusion: This study suggests that CBA-induced activation of S1PR2-mediated signaling pathways plays a critical role in obstructive cholestasis and may represent a novel therapeutic target for cholestatic liver diseases. (HEPATOLOGY 2017;65:2005-2018.
C holestasis represents the main clinical feature of cholangiopathies.
(1) Impaired bile formation or bile flow results in hepatic injury, fibrosis, and, eventually, cirrhosis. Liver transplantation is the only therapy for patients with end-stage cholestatic diseases. (2) Although tremendous efforts have been put into Abbreviations: AKT, protein kinase B; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ASBT, apical sodium-dependent bile acid transporter; AST, aspartate aminotransferase; BDL, bile duct ligation; BDO, bile duct obstruction; CBA, conjugated bile acid; CCA, cholangiocarcinoma; CK-19, cytokeratin-19; COX-2, cyclooxygenase 2; DMSO, dimethyl sulfoxide; ERK1/2, extracellular signal-regulated kinase 1 and 2; FXR, farnesoid X receptor; GPCRs, G-protein-coupled receptors; H&E, hematoxylin and eosin; HDACs, histone deacetylases; IHC, immunohistochemistry; IL, interleukin; LF, liver fibrosis; MSE, mouse small cholangiocyte; MLE, mouse large cholangiocyte; NF-OEB, nuclear factor kappa B; nSphK2, nuclear SphK2; p-AKT, phosphorylated AKT; p-ERK1/2, phosphorylated ERK1/2; SphK2, sphingosine kinase 2; S1P, sphingosine-1-phosphate; S1PR2, sphingosine 1-phosphate receptor 2; S1PR2 -/-, sphingosine 1-phosphate receptor 2 knockout; shRNA, short hairpin RNA; a-SMA, a-smooth actin; TCA, taurocholate; TbMCA, tauro-b-muricholic acid; WT, wild type. studying the pathophysiology of cholestatic disease progression over the past two decades, the underlying cellular/molecular mechanisms remain largely unknown.
Cholangiocytes are the major target cells involved in cholestatic liver diseases. Previous studies suggest that cholangiocyte proliferation may be linked to hepatic fibrosis. (3) There is growing evidence to indicate that cholangiocyte proliferation is regulated by multiple biological mediators, including neuropeptides, neurotransmitters, and hormones. (4) Bile duct obstruction (BDO) is a potent stimulus for cholangiocyte proliferation, especially for large cholangiocytes. (5) It is well-known that bile acids are important signaling molecules, which play a critical role in regulating hepatic metabolic pathways under physiological and pathological conditions. (6) Bile acids not only activate multiple protein kinase signaling pathways, such as protein kinases A and C and mitogenactivated protein kinases, but also activate several nuclear receptors (farnesoid X receptor [FXR] , pregnane X receptor, and vitamin D receptor) and G-protein-coupled receptors (GPCRs), such as TGR5 and sphingosine 1-phosphate receptor 2 (S1PR2). (7, 8) However, we do not have a complete understanding of how bile acid signals are integrated to regulate key events involved in cholangiocyte proliferation under cholestatic conditions. Sphingosine 1-phosphate (S1P) is an important bioactive lipid molecule involved in the regulation of fundamental cellular responses.
(9) S1P can directly act as an intracellular signaling molecule or function as the natural ligand of five different GPCRs (S1PR1-5).
(10) S1P and S1PRs have been shown to have differential roles in the regulation of cell proliferation, migration, and survival in different tissues and cells. (11) (12) (13) (14) It has been reported that S1P/S1PR3 signaling is involved in cholestasis-induced liver fibrosis (LF) (15) and S1P mediates bone-marrowderived macrophage migration through activation of S1PR2 and S1PR3 in the bile duct ligation (BDL) mouse model. (16) In addition, antagonism of S1PR2 selectively reduces portal vein pressure in BDL rodents. (17) Our previous studies showed that S1PR2 is highly expressed in the liver followed by S1PR1 and S1PR3 and the expression levels of S1PR4 and S1PR5 are too low to be detected. We also discovered that conjugated bile acids (CBAs) activated the ERK1/2 and protein kinase B (AKT) signaling pathways through S1PR2 in rodent hepatocytes. (18) Our recent studies further identified a critical role of S1PR2 in regulating sphingosine kinase 2 (SphK2) expression and expression of multiple hepatic genes. (19) Furthermore, we also showed that S1PR2 is responsible for CBA-mediated invasive growth, bile duct proliferation, and upregulation of cyclooxygenase 2 (COX-2) in cholangiocarcinoma (CCA) cells. (20, 21) In the current study, we report that activation of S1PR2 plays an essential role in CBA-induced cholangiocyte proliferation under cholestatic conditions. Inhibition of S1PR2 activation, using a specific chemical antagonist or knockdown of S1PR2 expression using a gene-specific short hairpin RNA (shRNA), significantly inhibited taurocholate (TCA)-induced cholangiocyte proliferation and migration. BDLinduced cholestatic liver injury was markedly reduced in S1PR2 knockout (S1PR2 -/-) mice. The chemical antagonist of S1PR2, JTE-013, also showed protective effect against BDL-induced liver injury. Our study suggests that targeting of CBA/S1PR2-mediated signaling pathways may have therapeutic potential for a subset of cholestatic liver diseases that currently lack effective therapies.
Materials and Methods

MATERIALS
S1P and JTE-013 were purchased from Cayman Chemical (Boston, MA). The Bio-Rad protein assay reagent, Precision Plus Protein Kaleidoscope Standards, and iQ SYBR Green Supermix were obtained from Bio-Rad (Hercules, CA). IRDye secondary antibody was from LI-COR (Lincoln, NE). FuGene HD transfection Reagent was from Promega (Madison, WI). TCA and other chemicals were from SigmaAldrich (St. Louis, MO).
CELL CULTURE
The immortalized normal mouse small cholangiocytes (MSE) and large cholangiocytes (MLE) were kind gifts from Dr. Gianfranco Alpini (Texas A&M Health Science Center) and were cultured in minimal essential medium containing 10% fetal bovine serum, penicillin G (100 U/mL), and streptomycin (100 lg/ mL) at 378C with 5% CO 2 in a humidified cell-culture incubator. Mouse primary cholangiocytes were isolated by an immunoaffinity method using a rat monoclonal antibody against epithelial cell adhesion molecule (from D.S.H.B., University of Iowa), an antigen expressed by all mouse cholangiocytes as described. (22) 
ANIMALS
All experiments and procedures involving mice were approved by the institutional animal care and use committee of Virginia Commonwealth University (Richmond, VA) and were conducted in accord with the Declaration of Helsinki, The Guide for the Care and Use of Animals (National Academies Press, Washington, DC, 1996) , and all applicable regulations. S1PR2 -/-mice were a kind gift from Dr. R. Proia (NIDDK). They have been well characterized and used in a number of studies. (19) All mice were bred in pathogen-free conditions with normal lighting, and wild-type (WT) and knockout mice were from the same litters. Both male and female mice (8-12 weeks) were used.
BDL MOUSE MODEL
The standard partial common BDL was performed as we described. (23) Briefly, cystic duct and the common bile duct were ligated using 7-0 nylon. Sham mice underwent similar laparotomy without BDL. At the end, the abdomen was closed by a 6-0 double-layer suture, and the mice were allowed to wake up on a heating pad. After 3 or 14 days, serum and bile were collected and liver tissues were harvested for isolation of primary cholangiocytes or processed for quantitative real-time RT-PCR, western blotting analysis, histology, and immunohistochemistry (IHC) analysis.
CELL INVASION ASSAYS
MLE cells were seeded in the Matrigel-coated upper chamber. Cells were pretreated with JTE-013 (10 lM) or vehicle dimethyl sulfoxide (DMSO) for 1 hour, then treated with TCA (100 lM), S1P (100 nM), or vehicle DMSO and incubated at 378C for 24 hours. Migrated cells were stained and analyzed as described. (21) 
MEASUREMENT OF TOTAL BILE ACIDS
Mouse serum was collected at the end of the in vivo study. Liver tissues were homogenized in radioimmunoprecipitation assay buffer. The amount of total bile acids was measured by using the total bile acids assay kit (Crystal Chem Inc., Downers Grove, IL), according to the manufacturer's instructions. Total bile acid content in liver tissues was normalized with protein concentration and expressed as lmol/mg protein.
MEASUREMENT OF LIVER FUNCTIONAL ENZYME ACTIVITIES
Activities of plasma aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) were measured using assay kits from Sigma-Aldrich.
MEASUREMENT OF HEPATIC HYDROXYPROLINE
Liver hydroxyproline content was measured using the assay kit from Sigma-Aldrich Sigma (St. Louis, MO). The amount of hydroxyproline was measured according to the manufacturer's instructions. The result was expressed as total hydroxyproline (lg) per milligram of liver sample.
HISTOPATHOLOGY ANALYSIS AND IHC
Liver tissue sections were collected and fixed in 4% paraformaldehyde in 0.1 M of phosphate-buffered saline at room temperature overnight. Regions of specimens were standardized for all mice. Paraffinembedded liver tissue was sectioned (5 lm), and hematoxylin and eosin (H&E) and Masson's trichrome staining were done by the histopathology core lab of Medical College Virginia Hospital. Expression of cytokeratin-19 (CK-19) was detected by IHC staining as described. (21) 
STATISTICAL ANALYSIS
All the experiments were repeated at least three times, and the results are expressed as mean 6 SE. One-way analysis of variance was used to analyze the differences between sets of data using GraphPad Prism software (GraphPad Software Inc., San Diego, CA). A value of P < 0.05 was considered statistically significant. (19) 
Results
S1PR2 IS THE PREDOMINANT S1PR EXPRESSED IN CHOLANGIOCYTES AND UP-REGULATED BY BDL
We have previously reported that S1PR2 is the predominant S1PR in hepatocytes and CCA cells. (18) CBA-induced activation of S1PR2 plays an important role in regulating hepatic lipid metabolism. (19) Previous studies reported that TCA protects cholangiocyte apoptosis and promotes large cholangiocyte proliferation. (5, (24) (25) (26) To determine whether S1PR2 is involved in TCA-induced cholangiocyte proliferation, we first examined the expression levels of different S1PRs in normal mouse cholangiocytes. S1PR2 is the predominant S1PR in both MSE and MLE (Fig. 1A,B) . The expression level of S1PR2 in MLE is higher than that in MSE. Consistent with realtime RT-PCR results, western blotting analysis indicated that S1PR2 is the major S1PR in cholangiocytes (Fig. 1C ). More interestingly, 3-day BDL had no significant effect on total hepatic S1PR2 expression, but significantly increased S1PR2 expression in mouse primary cholangiocytes (Fig. 1D,E) . Furthermore, 2-week BDL not only markedly increased S1PR2 mRNA level, but also increased S1PR2 protein level in the liver ( Fig. 1D and Supporting Fig. S1 ).
THE ROLE OF TCA-INDUCED ACTIVATION OF S1PR2 IN PROMOTING CHOLANGIOCYTE PROLIFERATION
BDO is a strong stimulus that promotes cholangiocyte proliferation and represents one of the major causes of cholestatic liver diseases. It has been long believed that direct toxicity of bile acids causes cholestatic liver injury. However, a recent study showed that the concentrations of unconjugated cytotoxic bile acids are too low to induce hepatocellular injury in BDL mice. (27) TCA is the major bile acid identified in mouse serum and liver post-BDL. (27) These studies indicated that TCA may play a critical role in BDLinduced cholestatic liver injury. In order to determine the mechanism underlying TCA-induced cholestatic liver injury, we first examined whether TCA can activate S1PR2 and further induce activation of downstream ERK1/2 and AKT signaling pathways in MLE cells. Both TCA and S1P significantly induced phosphorylated AKT (p-AKT) and phosphorylated ERK1/2 (p-ERK1/2) phosphorylation, which were inhibited by the S1PR2 antagonist, JTE-013 (Fig  2A) . Real-time PCR analysis further showed that TCA dose dependently increased S1PR2 mRNA expression levels in MLE (Fig. 2B) . We have previously reported that TCA-induced S1PR2 activation contributes to invasive growth of CCA cells. (21) We further examined whether TCA-and S1P-induced activation of S1PR2 is also involved in normal cholangiocyte proliferation. Down-regulation of S1PR2, using a specific lentiviral shRNA of S1PR2, completely blocked TCA-and S1P-induced cell proliferation in MLE (Fig. 2C,D) . In order to determine whether TCA-and S1P-induced activation of p-AKT and p-ERK1/2 signaling pathways is involved in cell proliferation, specific chemical inhibitors of ERK1/2 (U0126) and AKT (MK2206) were used. Both TCA-and S1P-induced cell proliferation was blocked by U0126 or MK2206 in MLE cells (Supporting Fig. S2 ). Similar to the findings in CCA cells, both TCA-and S1P-induced cell migration and invasion were inhibited by down-regulation of S1PR2 expression using a specific shRNA . C57/BL6 WT mice were subjected to sham operation or BDL for 3 days or 2 weeks. Total RNA was isolated. (E) Mouse primary cholangiocytes were isolated from sham control or BDL mice (3-day). mRNA levels of S1PR1, S1PR2, and S1PR3 were detected by real-time RT-PCR and normalized using glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Protein levels of S1PR1, S1PR2, and S1PR3 were detected by western blotting analysis. (A,B) ***P < 0.01, statistical significance relative to S1PR1; n 5 3; (C) Representative images of the immunoblottings for S1PR1-3 are shown. b-actin was used as a loading control. (D,E) *P < 0.05; **P < 0.01, statistical significance relative to sham control; n 5 3-5.
FIG. 2.
Role of S1PR2 in TCA/S1P-induced AKT and ERK1/2 activation and cholangiocyte proliferation. (A). MLE cells were pretreated with JTE-013 (10 lM) for 30 minutes, then treated with vehicle control (DMSO), TCA (100 lM), or S1P (1 lM) for 30 minutes. Protein levels of p-AKT, total AKT, p-ERK1/2, and T-ERK1/2 were determined by western blotting analysis. Representative images of immunoblottings for p-AKT, T-AKT, p-ERK, and T-ERK are shown. Relative density of p-ERK/T-ERK and p-AKT/T-AKT was determined by Image J software (NIH, Bethesda, MD). **P < 0.01, statistical significance relative to control; ## P < 0.01, statistical significance relative to the corresponding treatment group with and without JTE-013 (n 5 3). (B) MLE cells were treated with different amounts of TCA (0, 50, and 100 lM) for 24 hours. mRNA levels of S1PR2 were detected by real-time RT-PCR and normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. The relative amount of S1PR2 mRNA is shown. (C) MLE cells were transduced with purified lentiviral control shRNA (C-shRNA) or S1PR2 shRNA for 48 hours. The S1PR2 mRNA was measured by real-time RT-PCR and normalized with GAPDH as an internal control. (D) MLE cells were transduced with lentiviral C-shRNA or S1PR2 shRNA for 36 hours, then treated with vehicle control, TCA (100 lM), or S1P (1 lM) for 48 hours. Viable cells were analyzed using a Cellometer Vision CBA automatic cell counter. Relative cell number, compared to vehicle control group, is shown. Values represent the mean 6 SE of three independent experiments. Statistical significance relative to the vehicle control group (designated 5 1): *P < 0.05; **P < 0.01; ***P < 0.001; statistical significance relative to the C-shRNA group with the same treatment group, ## P < 0.01.
(Supporting Fig. S3 ) or inhibition of S1PR2 activation using JTE-013 (Fig. 3 ).
S1PR2 -/-MICE HAVE LOWER LEVELS OF BILE ACIDS IN SERUM AND LIVER POST-BDL
Previous studies have shown that BDL markedly increased bile acid levels in serum and liver. (27) In BDL mice, S1PR2 expression levels in liver and cholangiocytes were significantly increased (Fig. 1) . Next, we wanted to determine whether there was any link between S1PR2 and bile acid levels post-BDL. Both WT and S1PR2 -/-mice were subjected to a sham operation or BDL. After 2 weeks, serum and livers were harvested and total bile acid levels were measured using a commercial kit. BDL dramatically increased serum total bile acid levels as compared to sham control WT mice (Fig. 4) . However, in S1PR2 -/-mice, total bile acid levels in serum were significantly reduced compared to WT mice post-BDL. Similarly, BDLinduced increase of hepatic bile acid levels was significantly reduced in S1PR2 -/-mice (Fig. 4B ).
S1PR2 -/-MICE WERE PROTECTED FROM CHOLESTASIS-INDUCED LIVER INJURY
Cholestatic liver injury is mainly induced by CBAs in the BDL mouse model. (27) S1PR2 deficiency prevented bile acid accumulation in liver and serum after a 2-week BDL. In order to further determine whether S1PR2 -/-mice were protected from cholestasisinduced liver injury, we measured liver functional enzyme activities. AST and ALT levels were not changed significantly by BDL in either WT or S1PR2 -/-mice (Fig. 4C,D) . However, ALP activity was significantly increased after a 2-week BDL in WT mice. S1PR2 deficiency markedly reduced BDLinduced increase of ALP (Fig. 4E) . In addition, liver weight and spleen weight were increased by BDL, but not significantly different between WT and S1PR2 mice (Supporting Fig. S4 ). To examine the role of S1PR2 in cholestasis-induced LF, collagen content was determined by measurement of hydroxyproline content in livers. Hepatic hydroxyproline level was increased in WT mice post-BDL, but not in S1PR2 -/-mice, indicating that S1PR2 deficiency prevented BDL-induced LF (Fig. 4F) . To confirm this observation, we examined liver histology using H&E staining and Masson's trichrome staining. Two-week BDL significantly induced hepatic injury and LF in WT mice, but had less impact in S1PR2 -/-mice ( Fig.  5 and Supporting Figs. S5 and S6) . Consistently, real-time RT-PCR results showed that BDL significantly increased mRNA expression levels of collagen type I and a-smooth actin (a-SMA) in liver of WT mice, but not in that of S1PR2 -/-mice (Fig. 6A) .
FIG. 4.
Role of S1PR2 in BDL-induced increase of bile acid levels and fibrotic liver injury. WT and S1PR2 -/-mice were subjected to 2-week BDL or sham operation as described in Materials and Methods. The bile acids, AST, ALT, and ALP, and hydroxyproline levels in serum and liver were measured using commercial kits according to the manufacturer's instructions. Statistical significance relative to sham control, *P < 0.05; **P < 0.01; ***P < 0.001; n 5 5-7; statistical significance relative to WT BDL, *P < 0.05; n 5 5-7.
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Similarly, both collagen 1 and a-SMA mRNA levels were significantly increased in primary mouse cholangiocytes isolated from WT BDL mice, not from S1PR2 -/-BDL mice (Supporting Fig. S7 ). To further examine the effect of BDL on cholangiocyte proliferation, intrahepatic bile duct mass was evaluated by CK-19 IHC in paraffinembedded liver sections. BDL-induced cholangiocyte proliferation was significantly reduced in S1PR2 -/-mice (Fig. 6B) . In order to test whether inhibition of S1PR2 activation, using JTE-013, protected mice from BDLinduced cholestatic liver injury, WT sham-operated or BDL mice were treated with JTE-013 or vehicle control by intraperitoneal injection for 2 weeks. JTE-013 significantly reduced BDL-induced increase of ALT, ALP, and total bile acid levels in serum (Supporting Fig. S8 ). In addition, JTE-013 also reduced BDLinduced CK-19, Ki67, and collagen I expression (Supporting Fig. S9 ).
S1PR2 -/-MICE WERE PROTECTED FROM CHOLESTASIS-INDUCED INFLAMMATION
Inflammation plays a more important role than the direct cytotoxic effects of bile acids on hepatocytes in BDL-induced cholestatic liver injury. (27) BDL dramatically increased bile acid levels in liver and serum (Fig. 4A,B) . Our recent studies reported that TCA activated the ERK1/2/nuclear factor kappa B (NF -FIG. 6 . Role of S1PR2 in BDL-induced cholangiocyte proliferation and fibrosis. WT and S1PR2 -/-mice were subjected to 2-week BDL or sham operation as described in Materials and Methods. (A) mRNA levels of a-SMA and collagen type I were determined by real-time RT-PCR and normalized with GAPDH as an internal control. Statistical significance relative to sham control, **P < 0.01; n 5 5-7; statistical significance relative to WT BDL, # P < 0.05; OEB)/COX-2 signaling pathway through S1PR2 in human CCA cells. (20) To identify the potential mechanisms underlying CBA-mediated cholangiocyte proliferation under cholestasis conditions, we examined COX-2 expression levels in liver and primary cholangiocytes post-BDL. BDL significantly up-regulated COX-2 expression in liver and cholangiocytes of WT mice, but not in those of S1PR2 -/-mice (Fig. 7) . In addition, BDL significantly promoted bile duct proliferation (Supporting Fig. S10A ) and markedly down-regulated expression of the bile acid transporter, apical sodiumdependent bile acid transporter (ASBT), and FXR-a in cholangiocytes of WT mice (Supporting Fig. S10B ).
Discussion
We previously reported that TCA-mediated activation of S1PR2 contributed to invasive growth of CCA cells. (21) Our recent study further indicated that TCAinduced activation of S1PR2 promoted an inflammatory response by activating the ERK1/2/AKT/NF-kB signaling cascade, resulting in up-regulation of COX-2 expression and prostaglandin E2 production in human CCA cells. (20) It has been previously shown that cholestasis-induced liver injury is mainly attributed to inflammation and not the direct toxic effect of bile acids. (27) In the mouse BDL cholestasis model, more than 99% of bile acids in liver and serum are CBAs, mainly TCA and tauro-b-muricholic acid (TbMCA). Animals with histopathological signs of bile duct hyperplasia also have elevated serum levels of CBAs (TCA and glycocholate). (28) Metabolomics studies further showed that an altered bile acid profile was a key characteristic of liver injury. (29, 30) These studies suggest that CBAs may play a critical role in cholestasis-induced liver injury. We previously showed that CBAs activate S1PR2 in primary hepatocytes and in vivo using the chronic bile fistula rat model. (18) Recent studies further indicated that S1PR2 plays an important role in regulating hepatic metabolism through activation of SphK2. (19) However, the physiological and pathological relevance of TCA-induced activation of S1PR2 in cholangiocyte proliferation and cholestasis-induced liver injury is not clear. We propose that S1PR2 plays an essential role in cholestasis-induced liver injury by promoting an inflammatory response.
Similar to our previous findings in CCA cells, the current study demonstrated that S1PR2 is the predominant S1PR in mouse cholangiocytes. The mRNA level of S1PR2 was markedly increased in whole liver and primary cholangiocytes under cholestasis conditions (Fig. 1 ). Our current in vitro studies further demonstrated that TCA dose dependently increased S1PR2 expression (Fig. 2B) . TCA-induced ERK1/2 and AKT activation was correlated with cell proliferation and migration, which was blocked by inhibition of S1PR2 activation using a specific chemical antagonist or down-regulation of S1PR2 expression using a specific shRNA in MLE cells (Figs. 2 and 3 and Supporting Fig. S3 ). BDL-induced cholestatic liver injury was significantly reduced in S1PR2 -/-mice compared to
Role of S1PR2 in BDL-induced expression of COX-2.
(A) WT and S1PR2 -/-mice were subjected to 2-week BDL or sham operation as described in Materials and Methods. (B) Mouse primary cholangiocytes were isolated from WT and S1PR2 -/-mice after 3 days of BDL. mRNA levels of COX-2 in mouse liver were determined by real-time RT-PCR and normalized using GAPDH as an internal control. Statistical significance relative to sham control, *P < 0.05; n 5 5-7; statistical significance relative to WT BDL, # P < 0.05; n 5 5-7. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
WT mice as assessed by ALP level, hepatic hydroxyproline level, and liver histology (Figs. 4 and 5) . Proliferation of cholangiocytes is a major characteristic of cholestatic liver diseases. BDL of WT mice significantly induced cholangiocyte proliferation, as indicated by an increase of CK-19-positive bile ducts (Fig. 6B) . However, knockout of the gene encoding S1PR2 protected mice from BDL-induced bile duct proliferation and LF (Figs. 5B and 6A) . Moreover, BDL significantly induced COX-2 expression in liver and cholangiocytes of WT mice, but not in those of S1PR2 -/-mice (Fig. 7) . Our data suggest that CBAs-induced activation of S1PR2 and subsequent induction of an inflammatory response represent an important cellular mechanism underlying BDO-induced cholestatic liver injury. Our preliminary studies indicated that treatment of BDL mice with JTE-013 had some protective effect against cholestatic injury (Supporting Figs. S8 and S9). However, attributed to poor solubility of JTE-013, the bioavailability was not consistent. It will be necessary to develop a better delivery system for JTE-013 in order to test its therapeutic potential of this S1PR2 antagonist in in vivo animal models.
During the last two decades, extensive studies have been done to elucidate the functions of bile acids as important signaling molecules in regulating hepatic metabolism, initiating an inflammatory response, and inducing systemic functions. (6, 7, (31) (32) (33) Identification of bile-acid-activated GPCRs (TGR5 and S1PR2) opened new directions of bile acid research for the development of novel therapeutic targets of various liver diseases. (34) (35) (36) Recent studies by Reich et al. reported that TGR5 is essential for bile-aciddependent cholangiocyte proliferation both in cholangiocytes and in in vivo BDL mice. (37) In that study, BDL-induced biliary hyperplasia within the portal tracts was significantly reduced in TGR5 -/-mice, as indicated by reduced CK-19-positive bile ducts and lower numbers of Ki67-positive cholangiocytes. TGR5 expression was also up-regulated in human CCA tissue. However, there were no data reporting whether BDL-induced LF was also reduced in TGR5 -/-mice. TGR5 is mainly activated by the secondary bile acids and is coupled to the cAMP signaling pathway. Under physiological or cholestatic conditions, levels of secondary bile acids in liver are very low, whereas conjugated primary bile acid levels are much higher. In addition, TGR5 is not expressed in hepatocytes. Recent studies also reported that TGR5-mediated activation resulted in cholangiocyte hyperproliferation and cyst growth in an animal model of polycystic liver disease. (34) Although TGR5 is expressed in cholangiocytes, its expression level is much lower than that of S1PR2 (Supporting Fig. S11 ). Moreover, it has been shown that TGR5-mediated cholangiocyte proliferation in the BDL mouse model was independent of activation of the adenylyl cyclase/cAMP signaling pathway. (37) In our studies, we found that TGR5 expression was not affected by BDL or TCA, but S1PR2 expression is induced by BDL and TCA ( Figs.  1 and 2) . A recent study reported that activation of TGR5 attenuated inflammation and renal fibrosis in diabetic nephropathy by inhibiting S1PR2 expression and promoting S1PR2 internalization in glomerular mesangial cells. (38) It would be of interest to determine whether S1PR2 expression in cholangiocytes is altered in TGR5 -/-mice. Previous studies have reported that bile acids activated the epidermal growth factor receptor/ERK1/2 signaling pathway in hepatocytes in the absence of TGR5. (39) Our studies in human and rat CCA cells as well as mouse cholangiocytes demonstrated that bile-acid-induced ERK1/2 activation is linked to S1PR2. (20, 21) In current studies, we also showed that TCA-induced cell proliferation was
Model of BDO-induced liver fibrosis. BDO induces inflammation and CBAs, mainly TCA, in the liver. BDOinduced inflammation down-regulates ASBT and up-regulates S1PR2 in cholangiocytes. Extracellular TCA activates S1PR2, which further activates the ERK1/2-SphK2 signaling pathway. Activation of nuclear SphK2 increases levels of S1P in the nucleus, which further inhibits specific HDACs, resulting in an increase in acetylation of histones and up-regulation of genes involved in cell proliferation and metabolism. Activation of ERK1/2 also induces activation of NF-jB and increases COX-2 expression. CBA-induced S1PR2 activation plays a critical role in cholestasis-induced liver injury.
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inhibited by an ERK1/2 inhibitor (Supporting Fig.  S2 ). Our unpublished data in Mdr2 -/-mice, a wellestablished mouse model for primary sclerosing cholangitis, indicated that increased hepatic S1PR2 expression level was correlated to severity of cholestasisinduced LF, but TGR5 expression level decreased as fibrosis progressed (data not shown). In total, these studies suggest that S1PR2 is an important player in cholestatic liver injury.
Inflammation is an important contributor to cholestasis-induced liver injury. (40) S1P and S1PRs have been identified as key players in various fibrotic diseases, including LF. (16, (41) (42) (43) (44) (45) Recent studies reported that S1PR2/3-mediated homing of bone-marrow-derived immune cells contributes to cholestasis-induced liver fibrosis. (13, 16, 46) Bile-acid-induced ERK1/2 activation not only up-regulates proinflammatory cytokines, such as macrophage inflammatory protein 2, but also increases expression of interleukin (IL)-23, a key regulator of IL-17A production. Activation of IL-23/IL-17A further enhances bile-acid-mediated hepatic inflammation during obstructive cholestasis. (47) If and how S1PR2 is involved in communication among cholangiocytes, immune cells, and hepatocytes under cholestatic conditions remains to be further examined.
In summary, our current results suggest that S1PR2 is a crucial GPCR that mediates CBA-induced liver injury under cholestasis conditions. Accumulation of CBAs attributed to BDO with subsequent inflammation results in down-regulation of ASBT and activation of S1PR2, which further activates the ERK1/2 signaling pathway (Fig. 8) . Our recent study reported that TCA/S1PR2-mediated ERK1/2 activation phosphorylates nuclear SphK2 (nSphK2), which controls nuclear S1P levels. (19) Nuclear S1P is a powerful inhibitor of histone deacetylases (HDACs) HDAC1 and HDAC2. (48, 49) Increase of histone acetylation will promote the transcriptional activity of key genes involved in regulating cell growth and hepatic lipid metabolism. Activation of ERK1/2 also can activate NF-OEB, which induces expression of various inflammatory genes including COX-2. Both cell proliferation and inflammation are key contributors to promoting fibrosis under cholestasis conditions (Fig. 8) .
